Anovo Surgical System, the first and only FDA-authorized surgical robot with features designed to mimic human arms and provide human level dexterity has been acquired by Lee Health. The news was announced today by Momentis Surgical™ Ltd.
The Anovo Surgical System will be available at Gulf Coast Medical Center. The Anovo Surgical System is designed to enable the less invasive vaginal approach for benign gynecological procedures including hysterectomies. The less invasive approach and improved dexterity position Anovo to provide a better surgical experience that may improve clinical outcomes and can be made available to a wider patient population.
Approximately 600,000 hysterectomies are performed annually in the U.S.i and a vaginal approach is well documented as providing significant clinical benefits, including less patient pain and scarring, shorter recovery times and reduced infection rates, compared to other approaches.ii Today this less invasive approach is used in only 16 percentiii of hysterectomies due to anatomical and technical limitations. The Anovo System is designed to overcome these limitations and offer patients faster recovery times, less pain and to enable virtually no visible scars on the abdomen.
“Lee Health is pleased to offer the Anovo Surgical System as an option for our patients,” said Jonathan Velez, MD, Chief Physician and Operations Executive at Gulf Coast Medical Center, a Lee Health hospital. “This illustrates our ongoing commitment to embracing technology and advancing the care we provide to our patients and our community.”
“We are excited to partner with Lee Health, a known leader in adopting robotic technology to better serve their patients,” added Dvir Cohen, CEO and Co-Founder of Momentis. “By offering the most advanced technology, their surgeons are empowered knowing they can offer a better surgical experience and improved outcomes to their female patients.”
The Anovo System is indicated for use in single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures including benign hysterectomy, salpingectomy, oophorectomy, adnexectomy, and ovarian cyst removal. Multiple instruments can be introduced to the body through a single portal and the unprecedented articulation offers optimal access and working angles. Anovo requires a much smaller footprint and costs significantly less than conventional robotic systems, making it possible for more hospitals and ambulatory surgery centers to acquire the system and offer more patients the benefits of less invasive robotic surgery. The Anovo System was granted de novo marketing authorization from the U.S. Food and Drug Administration (FDA) in February 2021.
